Mother-to-child transmission (MTCT) In 'About PregCOV-19LSR' ConferencesAbout PregCOV-19LSRProtocolCOVID-19 in Pregnancy: webinar seriesMother-to-child transmissionPrevalencePresentationMother outcomesBaby outcomesRisk factorsDiagnosingTreatmentPublications Back to 'PregCOV-19LSR' What is the risk of mother-to-child SARS-Cov-2 transmission a) in utero, b) intrapartum, and c) postpartum? What is the presence and persistence of the virus in amniotic fluid, cord blood, placenta, neonatal throat swabs, vaginal fluids, faeces, serology (IgM, IgG) and breast milk? Transmission risks to baby Version 6: updated 25th April 2022 Overall 2.7% (95% confidence interval 2.1 to 3.5%; 210 cohort studies, 24,040 babies) of babies born to mothers diagnosed with SARS-CoV-2 infection tested positive by reverse transcriptase polymerase chain reaction (RT-PCR). 2.2% of babies (95% CI 0.7 to 4.4%) tested positive within the first 24 hours of birth (35 cohorts, 2769 babies). Of the 1107 SARS-CoV-2 positive babies with relevant data, 32 had confirmed mother-to-child transmission: 10 in-utero live births (787 assessed), 10 in-utero foetal demise (70 assessed), three intrapartum (35 assessed), and nine during the early postnatal period (144 assessed). Maternal factors such as severe COVID-19 infection (odds ratio 3.5, 95% CI 1.5 to 8.1; 20 studies, 5,545 women), death (14.1, 4.1 to 48.0; 7 studies, 725 women), postnatal infection of SARS-CoV-2 (5.0, 1.2 to 20.1; 12 studies, 750 women), caesarean section (1.4, 1.1 to 1.8; 58 studies, 11,139 women), and skin-to-skin contact (0.4, 0.2 to 0.7, 3 studies, 1,101 women) were associated with SARS-CoV-2 positivity in offspring. RT-PCR positivity rates in offspring varied between geographical regions, ranging from 0.1% (0.0% to 0.5%) in studies from North America to 8.5% (4.6% to 13.3%) in studies from Latin America and the Caribbean. The types and timing of tests used to diagnose SARS-CoV-2 infection in babies varied between studies. Clinical outcomes of babies born to mothers with SARS-CoV-2 infection were inconsistently reported. (v6.0 last search update on 25 April 2022; findings may change as new evidence emerges) Disclaimer: The findings have not yet been peer reviewed and the sources cited should be checked. Any views expressed are those of the authors and not necessarily those of their institutions and organisations Previous versions Version 5: 3 August 2021 Version 4: 29 November 2020 Version 3: 7 October 2020 Version 2: 28 May 2020 Version 1: 4 May 2020 Structured research question (PICO) Mother-to-child transmission risk of COVID-19 infection Population Babies born to mothers with suspected/confirmed COVID-19 Exposure In-utero, intrapartum, postpartum Comparator - Outcomes Offspring COVID infection status (confirmed, probable, possible, unlikely, not infected)Viral levels in amniotic fluid, cord blood, vaginal fluids, breast milk, neonatal throat swabs, placenta; duration of viral shedding after COVID-19 symptom onset, after clinical resolution of signs/symptoms Study design Observational studies Findings Full details to be published shortly. Currently undergoing peer review.